GET DAILY SIGNALSBioMarin (BMRN) Readies Q3 2026 Earnings Amid Integration and Pipeline Outlays
Key Takeaways
- BioMarin is scheduled to report its third-quarter 2026 results after the market close on Monday, October 26, 2026, with a conference call at 4:30 p.m. ET.
- Zacks consensus calls for adjusted earnings of about $1.35 per share on revenue of roughly $1.03 billion, which would represent year-over-year revenue growth of approximately 33%.
- The company has already disclosed a $283 million in-process research and development (IPR&D) charge for the quarter, which it says will reduce both GAAP and non-GAAP diluted EPS by about $1.50.
- Including that charge, BioMarin has projected non-GAAP diluted EPS of about $1.25 for the quarter, underscoring how pipeline investment is weighing on near-term profitability.
- Investors will be watching VOXZOGO demand, the integration of the newly acquired Galafold and Pombiliti + Opfolda franchises, and any update to full-year 2026 adjusted EPS guidance of $4.90 to $5.10.
- For more detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages.
- Readers can also explore Trending AI Robots for AI-driven trading ideas and market signals.
Putting the Quarter in Perspective
BioMarin’s third-quarter report comes at a key juncture in its ongoing shift. The rare-disease biotech completed its roughly $4.8 billion acquisition of Amicus Therapeutics earlier in 2026, bringing Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease into its portfolio. That transaction helped drive revenue growth of about 20% in the second quarter, with sales reaching nearly $990 million. At the same time, the company has signaled heavy reinvestment in its pipeline, highlighted by the sizable research-and-development charge ahead of this release. For investors, the quarter will reveal whether the newly added products can maintain momentum even as higher spending and acquisition-related costs pressure results.
What Analysts Are Expecting
Estimates differ somewhat depending on how the announced $283 million IPR&D expense is accounted for. Zacks consensus points to adjusted EPS of $1.35 on revenue of about $1.03 billion, up roughly 32.7% from the year-ago quarter, while MarketWatch’s average sits near $1.34. BioMarin has indicated that the IPR&D charge will reduce both GAAP and non-GAAP diluted EPS by approximately $1.50, and it has projected non-GAAP diluted EPS of about $1.25 for the quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Attention will center on VOXZOGO sales and patient trends, growth in the Metabolic Conditions portfolio, and the full-year 2026 non-GAAP EPS guidance of $4.90 to $5.10. BioMarin has beaten EPS estimates in six of its last seven quarters, most recently posting $1.20 per share versus a $0.95 consensus in Q2 2026.
Market Sentiment Heading Into the Print
Investor sentiment appears cautiously constructive. Analyst consensus stands at a “Moderate Buy,” with an average price target near $88, well above the stock’s recent trading range in the mid-$50s, according to MarketBeat data. The shares have trailed the broader market in recent months, partly reflecting the pre-announced R&D charge and questions around VOXZOGO competition in the U.S. Investors will monitor whether the company reaffirms or adjusts its full-year guidance and whether management provides concrete detail on integration cost savings, which the company has targeted at about $220 million in annual run-rate synergies by 2028. A clear revenue beat or an upward revision to guidance could matter more to the stock’s reaction than the headline EPS figure, which is expected to be held down by the pipeline charge.
What to Watch After the Report
Once the numbers are out, attention will turn to execution on three main fronts.
First, investors will track VOXZOGO’s resilience. The growth therapy has encountered a new U.S. competitor, and management has noted that roughly 90% of U.S. patients remained on therapy through July. Sustained patient retention and expansion into younger age groups will be central to the product’s path toward becoming BioMarin’s first $1 billion franchise.
Second, the Amicus integration will stay in focus. Management has cited peak revenue potential of roughly $1.4 billion for Galafold and $1.2 billion for Pombiliti + Opfolda, with significant cost synergies expected over the next two years. Progress on diagnosis, patient switching, and international launches will determine how quickly those targets are reached.
Finally, pipeline milestones and balance-sheet discipline remain important. The $283 million IPR&D charge underscores management’s willingness to invest in clinical-stage assets, while acquisition-related debt adds interest expense of about $200 million annually. Investors should watch how the company balances innovation spending with deleveraging as it works toward EPS accretion from the deal.
Using AI Tools to Refine the View
From what I see, having access to specialized screening tools helps put individual company data into broader context. One resource I turn to regularly is Tickeron’s AI Screener, which lets users filter stocks and ETFs by technical patterns, fundamentals, and AI-driven signals. It has proven useful for quickly identifying comparable names or spotting emerging trends without manually combing through hundreds of filings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BMRN's RSI Oscillator ascends from oversold territory
The RSI Oscillator for BMRN moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 23 of the 30 cases the stock moved higher. This puts the odds of a move higher at 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 62 cases where BMRN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on BMRN as a result. In 53 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for BMRN just turned positive on October 20, 2026. Looking at past instances where BMRN's MACD turned positive, the stock continued to rise in 30 of 50 cases over the following month. The odds of a continued upward trend are 60%.
Following a +3.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in 166 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
BMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
BMRN moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BMRN crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
The Aroon Indicator for BMRN entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.713) is normal, around the industry mean (3.035). BMRN's P/E Ratio (151.216) is considerably higher than the industry average of (-1.360). Projected Growth (PEG Ratio) (0.348) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (3.727) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of innovative pharmaceuticals for serious diseases & medical conditions
Industry Biotechnology
Advertisement